Predictors of RBD progression and conversion to synucleinopathies
There is a variety of potential biomarkers for monitoring disease progression and predicting iRBD conversion into synucleinopathies. A combined multimodal biomarker model could offer a more sensitive and specific tool. Further longitudinal studies are warranted to iRBD as a high-risk population for early neuroprotective interventions and disease-modifying therapies. CLICK TO REVIEW
Predictors of RBD progression and conversion to synucleinopathies Read More »